Abstract
Objective: To examine the relationship between alcohol, both the amount and type, and cognitive decline in a cohort of Alzheimer’s disease (AD) patients.
Methods: A cohort of 360 patients with early AD in New York, Boston, Baltimore and Paris were followed-up biannually for up to 19.28 years. At each visit, the cognitive profile of the patients was assessed using the modified Mini-Mental State Examination (mMMSE), and patients’ alcohol intake, including beverage type, was reported by patients’ primary caregivers. General estimating equation analysis was used to determine whether baseline alcohol use was associated with the rate of cognitive decline.
Results: Heavy drinkers (8 or more alcoholic drinks/week) had a faster cognitive decline, deteriorating 1.849 more points on their mMMSE score annually compared to abstainers (P = 0.001), or 2.444 more points compared to mild-moderate drinkers (1-7 alcoholic drinks/week) (P = 0.008). There was no significant difference when comparing mild-moderate drinkers to abstainers. Increasing standard drinks of hard liquor, but not beer or wine, was also associated with a faster rate of cognitive decline (β = -0.117 P = 0.001).
Conclusion: Heavy alcohol consumption and more hard liquor are associated with a faster rate of cognitive decline in AD patients, suggesting that they may hasten progression of AD. Our results suggest that alcohol drinking habits might alter the course of AD.
Keywords: Alcohol, Alzheimer's disease, cognitive decline, dementia, disease progression, hard liquor, risk factors in epidemiology.
Current Alzheimer Research
Title:The Association Between Alcohol Use and the Progression of Alzheimer’s Disease
Volume: 13 Issue: 12
Author(s): Devorah Heymann, Yaakov Stern, Stephanie Cosentino, Oksana Tatarina-Nulman, Jhedy N. Dorrejo and Yian Gu
Affiliation:
Keywords: Alcohol, Alzheimer's disease, cognitive decline, dementia, disease progression, hard liquor, risk factors in epidemiology.
Abstract: Objective: To examine the relationship between alcohol, both the amount and type, and cognitive decline in a cohort of Alzheimer’s disease (AD) patients.
Methods: A cohort of 360 patients with early AD in New York, Boston, Baltimore and Paris were followed-up biannually for up to 19.28 years. At each visit, the cognitive profile of the patients was assessed using the modified Mini-Mental State Examination (mMMSE), and patients’ alcohol intake, including beverage type, was reported by patients’ primary caregivers. General estimating equation analysis was used to determine whether baseline alcohol use was associated with the rate of cognitive decline.
Results: Heavy drinkers (8 or more alcoholic drinks/week) had a faster cognitive decline, deteriorating 1.849 more points on their mMMSE score annually compared to abstainers (P = 0.001), or 2.444 more points compared to mild-moderate drinkers (1-7 alcoholic drinks/week) (P = 0.008). There was no significant difference when comparing mild-moderate drinkers to abstainers. Increasing standard drinks of hard liquor, but not beer or wine, was also associated with a faster rate of cognitive decline (β = -0.117 P = 0.001).
Conclusion: Heavy alcohol consumption and more hard liquor are associated with a faster rate of cognitive decline in AD patients, suggesting that they may hasten progression of AD. Our results suggest that alcohol drinking habits might alter the course of AD.
Export Options
About this article
Cite this article as:
Heymann Devorah, Stern Yaakov, Cosentino Stephanie, Tatarina-Nulman Oksana, Dorrejo N. Jhedy and Gu Yian, The Association Between Alcohol Use and the Progression of Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (12) . https://dx.doi.org/10.2174/1567205013666160603005035
DOI https://dx.doi.org/10.2174/1567205013666160603005035 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High-Risk Neuroblastoma: Poor Outcomes Despite Aggressive Multimodal
Therapy
Current Cancer Therapy Reviews LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Infectious Disorders - Drug Targets Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease
Current Alzheimer Research Advances in Methods for Therapeutic Peptide Discovery, Design and Development
Current Pharmaceutical Biotechnology Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators
Current Medicinal Chemistry Metabolic Aspects of Prion Diseases: An Overview
Current Drug Targets Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors
Current Topics in Medicinal Chemistry Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Neuroprotection for Amyotrophic Lateral Sclerosis: Role of Stem Cells, Growth Factors, and Gene Therapy
Central Nervous System Agents in Medicinal Chemistry Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Current Drug Targets for Modulating Alzheimer's Amyloid Precursor Protein: Role of Specific Micro-RNA Species
Current Medicinal Chemistry Cilostazol as a Unique Antithrombotic Agent
Current Pharmaceutical Design The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Exploiting Internal Ribosome Entry Sites in Gene Therapy Vector Design
Current Gene Therapy